肺癌是全世界最常见的肺原发性恶性肿瘤,随着世界各国工业化进程的不断发展,特别是工业发达国家,肺癌的发病率和病死率均迅速上升,约2/3的患者被诊断出该病时已处于晚期[1],死于癌症的男性病人中肺癌已居首位。在中国,肺癌在大城市已占恶性肿瘤发病率和死亡率的首位。为提高肺癌患者的治愈率,延长生存期,改善生存质量,多学科综合治疗晚期肺癌已成共识,其中生物靶向治疗被视为治疗 Lung cancer is the most common primary lung cancer in the world. With the continuous development of industrialization in various countries in the world, especially in industrialized countries, the incidence and mortality of lung cancer are rapidly rising. About two-thirds of patients are diagnosed The disease is already late [1], lung cancer has been the top among male patients who died of cancer. In China, lung cancer accounts for the highest incidence and mortality of malignant tumors in major cities. To improve the cure rate of lung cancer patients, prolong survival and improve the quality of life, multi-disciplinary treatment of advanced lung cancer has become the consensus, of which biological targeted therapy is considered as treatment